Literature DB >> 6990903

Trichilemmoma of eyelid and eyebrow. A clinicopathologic study of 31 cases.

A A Hidayat, R L Font.   

Abstract

Thirty-one cases of trichilemmoma of the eyelid and eyebrow were studied. All lesions were solitary, small, and asymptomatic. Unlike basal cell carcinoma of the eyelid, trichilemmoma rarely involves the lid margin or the inner canthus. The age range of our patients was from 22 to 88 years old (mean, 56 years). There were 19 men and 12 women. The most frequent clinical diagnoses were verruca vulgaris and cutaneous horn. Typically, the tumor displayed a lobular pattern and was composed mostly of glycogen-rich clear cells. The periphery of the lobules showed palisading of columnar cells and a distinct basement membrane. Histologically, the tumor was frequently misinterpreted as basal cell carcinoma. Review of the literature, including our own series, discloses that the eyelid is the second most common site for trichilemmoma after the nose.

Entities:  

Mesh:

Year:  1980        PMID: 6990903     DOI: 10.1001/archopht.1980.01020030838007

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  4 in total

1.  Benign hair-follicle derived tumours in the differential diagnosis of basal-cell carcinoma of the eyelids: a clinicopathological comparison.

Authors:  W Simpson; A Garner; J R Collin
Journal:  Br J Ophthalmol       Date:  1989-05       Impact factor: 4.638

2.  Eyelid skin trichilemmoma and underlying local malignancy: is an aggressive treatment necessary?

Authors:  Christine Anggun Putri; Hardeep Singh Mudhar; Adam Meeney; Jennifer H Y Tan
Journal:  BMJ Open Ophthalmol       Date:  2020-06-25

Review 3.  Pathology of eyelid tumors.

Authors:  Jacob Pe'er
Journal:  Indian J Ophthalmol       Date:  2016-03       Impact factor: 1.848

4.  Masquerades less known: Case report of benign hair follicle tumors.

Authors:  Jayashree Bakthavatchalam; Jayagayathri Rajagopalan; Dayakar Yadalla
Journal:  Indian J Ophthalmol       Date:  2018-10       Impact factor: 1.848

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.